<DOC>
	<DOCNO>NCT02189577</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety CHF 5259 ( glycopyrrolate bromide ) treatment COPD patient .</brief_summary>
	<brief_title>Efficacy Safety Glycopyrrolate Bromide COPD Patients</brief_title>
	<detailed_description>A Multinational , Multicentre , Randomised , Double Blind , Placebo-Controlled , 2-way Crossover Study Evaluate Efficacy Safety Glycopyrrolate Bromide Administered Via pMDI ( CHF 5259 ) , Treatment Patients With Chronic Obstructive Pulmonary Disease</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female adult ( 40 ≤ age ≤ 80 year ) diagnosis COPD Current smokers exsmokers A postbronchodilator FEV1 &lt; 60 % predict normal value postbronchodilator FEV1/FVC &lt; 0.7 Positive response reversibility test screening define change FEV1 ≥ 5 % . BDI score ≤ 10 Patients free exacerbation least 1 month Pregnant lactate woman Diagnosis asthma Patients treat exacerbation 4 week prior screen visit Patients treat longacting antihistamine unless take stable regimen least 2 month prior screen maintain constant study take PRN Patients require long term ( least 12 hour daily ) oxygen therapy chronic hypoxemia Known respiratory disorder COPD Patients clinically significant cardiovascular condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Obstructive Pulmonary disease</keyword>
	<keyword>COPD</keyword>
</DOC>